MA38136B1 - Treatment or prevention of cardiovascular events by administration of a colchicine derivative - Google Patents

Treatment or prevention of cardiovascular events by administration of a colchicine derivative

Info

Publication number
MA38136B1
MA38136B1 MA38136A MA38136A MA38136B1 MA 38136 B1 MA38136 B1 MA 38136B1 MA 38136 A MA38136 A MA 38136A MA 38136 A MA38136 A MA 38136A MA 38136 B1 MA38136 B1 MA 38136B1
Authority
MA
Morocco
Prior art keywords
group
alkyl
optionally substituted
formula
independently represent
Prior art date
Application number
MA38136A
Other languages
French (fr)
Other versions
MA38136A1 (en
Inventor
Mark Nidorf
Original Assignee
Murray & Poole Enterprises Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2012904828A external-priority patent/AU2012904828A0/en
Application filed by Murray & Poole Enterprises Ltd filed Critical Murray & Poole Enterprises Ltd
Priority claimed from PCT/AU2013/001261 external-priority patent/WO2014066944A1/en
Publication of MA38136A1 publication Critical patent/MA38136A1/en
Publication of MA38136B1 publication Critical patent/MA38136B1/en

Links

Landscapes

  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention concerne un procédé de traitement ou de prévention d'un événement cardiovasculaire chez un sujet atteint d'une maladie vasculaire athérosclérotique, ledit procédé comprenant l'étape suivante : b) administration d'une quantité thérapeutiquement efficace d'un composé de formule (i), d'un dérivé connu de colchicine et/ou d'un sel de celui-ci où : r1, r2, r3, r4, r9, r10, r11 et r12 représentent indépendamment un atome d'hydrogène, un groupe alkyle en c1-4, un groupe alcényle en c2-4, un groupe cycloalkyle en c3-6, un atome d'halogène, un groupe haloalkyle en c1-4, un groupe nitro, un groupe amino, un groupe acylamino en c2-4, un groupe dialkylamino ou alkyle en c1-4, un groupe hydroxyle, un groupe alcoxy en c1-4, un groupe alkylthio en c1-4, un groupe de formule -so2n(rx)2 ou so2rx dans laquelle rx est un groupe alkyle en c1-4, un groupe acyloxy en c1-4, ou un groupe phényle facultativement substitué, un groupe phénoxy facultativement substitué ; r7 et r8 représentent indépendamment un atome d'hydrogène, un groupe alkyle en c1-4 ou un groupe acyle en c1-4 ; et r5', r5", r6' et r6" représentent indépendamment un atome d'hydrogène, un groupe alkyle en c1-4, un groupe alcényle en c2-4, un groupe cycloalkyle en c3-6, un atome d'halogène, un groupe haloalkyle en c1-4, un groupe nitro, un groupe amino, un groupe acylamino en c2-4, un groupe hydroxyle, un groupe alcoxy en c1-4 ou un groupe alkylthio en c1-4, un groupe de formule - so2n(rx)2 ou so2rx dans laquelle rx est un groupe alkyle en c1-4, un groupe acyloxy en c1-4, ou un groupe phényle facultativement substitué.The present invention relates to a method for treating or preventing a cardiovascular event in a subject suffering from atherosclerotic vascular disease, said method comprising the following step: b) administering a therapeutically effective amount of a compound of formula (i) a known derivative of colchicine and / or a salt thereof wherein: r1, r2, r3, r4, r9, r10, r11 and r12 independently represent a hydrogen atom, an alkyl group in C 1-4, a C 2-4 alkenyl group, a C 3-6 cycloalkyl group, a halogen atom, a C 1-4 haloalkyl group, a nitro group, an amino group, a C 2-4 acylamino group; , a dialkylamino or C1-4 alkyl group, a hydroxyl group, a C1-4 alkoxy group, a C1-4 alkylthio group, a group of the formula -so2n (rx) 2 or so2rx wherein rx is an alkyl group at C1-4, a C1-4 acyloxy group, or an optionally substituted phenyl group, an optionally substituted phenoxy group ue; r7 and r8 independently represent a hydrogen atom, a C1-4 alkyl group or a C1-4 acyl group; and R5 ', R5 ", R6' and R6" independently represent a hydrogen atom, a C1-4 alkyl group, a C2-4 alkenyl group, a C3-6 cycloalkyl group, a halogen atom, a C1-4 haloalkyl group, a nitro group, an amino group, a C2-4 acylamino group, a hydroxyl group, a C1-4 alkoxy group or a C1-4 alkylthio group, a group of the formula - so2n (rx) 2 or so2rx wherein rx is a C1-4 alkyl group, a C1-4 acyloxy group, or an optionally substituted phenyl group.

MA38136A 2012-11-02 2013-11-01 Treatment or prevention of cardiovascular events by administration of a colchicine derivative MA38136B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2012904828A AU2012904828A0 (en) 2012-11-02 Treatment and Prevention of Coronary Thrombosis
PCT/AU2013/001261 WO2014066944A1 (en) 2012-11-02 2013-11-01 Treatment or prevention of cardiovascular events via the administration of a colchicine derivative

Publications (2)

Publication Number Publication Date
MA38136A1 MA38136A1 (en) 2017-08-31
MA38136B1 true MA38136B1 (en) 2019-03-29

Family

ID=60450322

Family Applications (2)

Application Number Title Priority Date Filing Date
MA38136A MA38136B1 (en) 2012-11-02 2013-11-01 Treatment or prevention of cardiovascular events by administration of a colchicine derivative
MA44940A MA44940B1 (en) 2012-11-02 2013-11-01 Treatment or prevention of cardiovascular events by administration of a colchicine derivative

Family Applications After (1)

Application Number Title Priority Date Filing Date
MA44940A MA44940B1 (en) 2012-11-02 2013-11-01 Treatment or prevention of cardiovascular events by administration of a colchicine derivative

Country Status (1)

Country Link
MA (2) MA38136B1 (en)

Also Published As

Publication number Publication date
MA38136A1 (en) 2017-08-31
MA44940A1 (en) 2020-05-29
MA44940B1 (en) 2022-04-29

Similar Documents

Publication Publication Date Title
MY177898A (en) Treatment or prevention of cardiovascular events via the administration of a colchicine derivative
RU2009102278A (en) S1P RECEPTOR MODULATORS FOR THE TREATMENT OF MULTIPLE SCLEROSIS
RU2010126056A (en) ORGANIC COMPOUNDS
RU2006112427A (en) 2-pyridone derivatives as neutrophil elastase inhibitors and their use
MA33904B1 (en) Use of adrenal hormone change factor
RU2011106364A (en) LIQUID COMPOSITIONS
MA37866B1 (en) Aza-indazole or diaza-indazole derivatives for the treatment of pain
MA38385A1 (en) New composition for non-alcoholic fatty liver disease (nafld)
MA29272B1 (en) SPIROCETAL DERIVATIVE AND ITS USE AS A MEDICINE AGAINST DIABETES
RU2521286C2 (en) Sphingosine-1-phosphate (s1p) receptor modulators and using them for treating muscular tissue inflammation
US6563009B1 (en) Vasodilator cannabinoid analogs
RU2015117647A (en) NEW PYRAZOLE DERIVATIVES
MA38275B1 (en) Saturated and N-acylated nitrogen heterocycles potentiating the activity of an antibiotic active against mycobacteria
RU2008136762A (en) CYCLIC SULPHONES AS YOUR INHIBITORS
WO2012131656A3 (en) Compounds for use as therapeutic agents affecting p53 expression and/or activity
RU2012150501A (en) ANTI-CANCER STEROID LACTONS UNSATURATED IN REGULATION 7 (8)
TN2015000240A1 (en) Aminocyclobutane derivatives, method for preparing same and the use thereof as drugs
MA38114A1 (en) New selective androgenic modulators
MA35363B1 (en) Use of a compound organization in the treatment of noonan syndrome
MA29559B1 (en) 4,5-DIARYLPYRROLE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USE THEREOF
MA38136B1 (en) Treatment or prevention of cardiovascular events by administration of a colchicine derivative
RU2014123690A (en) THERAPEUTIC FOR ARTHROSIS
RU2009138028A (en) NEW PREVENTIVE AND / OR MEDICINE AGAINST NEUROPATHIC PAIN
MA56324B1 (en) ARGINASE INHIBITORS AND METHODS OF USE
RU2009138032A (en) NEW PREVENTIVE AND / OR MEDICINE AGAINST DIABETIC NEUROPATHY